Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | AHR | P35869 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2490426 | 0.87 | KMT2A (0.75) | GAATDP1KMT2ANR1I2AHR | |
| Propazine SCHEMBL29366712 | 0.85 | GAA (0.73) | GAATDP1KMT2ALMNAALDH1A1 | |
| Atrazine SCHEMBL9117361 | 0.85 | GAA (0.73) | GAATDP1KMT2ALMNAALDH1A1 | |
| Propazine SCHEMBL9379274 | 0.85 | GAA (0.73) | GAATDP1KMT2ALMNAALDH1A1 | |
| Propazine SCHEMBL9092745 | 0.85 | GAA (0.73) | GAATDP1KMT2ALMNAALDH1A1 | |
| Atrazine SCHEMBL29353679 | 0.85 | GAA (0.73) | GAATDP1KMT2ALMNAALDH1A1 | |
| Atrazine SCHEMBL1516439 | 0.85 | GAA (0.73) | GAATDP1KMT2ALMNAALDH1A1 | |
| Atrazine SCHEMBL4306269 | 0.85 | GAA (0.73) | GAATDP1KMT2ALMNAALDH1A1 | |
| Atrazine SCHEMBL20723465 | 0.85 | GAA (0.73) | GAATDP1KMT2ALMNAALDH1A1 | |
| Atrazine SCHEMBL36936 | 0.85 | GAA (0.73) | GAATDP1KMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210363115-A2 | CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2021-11-25 | — | — | US | disclosed |
| US-20210163426-A1 | CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2021-06-03 | — | — | US | disclosed |
| EP-0751170-B1 | Silicone derivatives, their production and use | CHIBA FLOUR MILLING (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-5859243-A | AMINOSILICONES HAVING PYRIMIDINYL GROUPS BOUND TO THE AMINO GROUPS; USED TO GEL SILICONE OIL OR TO INCREASE THE VISCOSITY STABLY AND HOMOGENEOUSLY; BASES FOR COSMETICS, DRUGS, INDUSTRIAL MATERIAL; FEEL; TEXTURE | CHIBA FLOUR MILLING CO., LTD. (JP) | 1999-01-12 | — | — | US | disclosed |
| US-5712391-A | POLYSILOXANES MODIFIED WITH TRIAZINE GROUPS AND DIAMINE COMPOUNDS FOR COSMETICS | CHIBA FLOUR MILLING CO., LTD. (JP) | 1998-01-27 | — | — | US | disclosed |
| EP-0751170-A2 | Silicone derivatives, their production and use | Chiba Flour Milling Co., Ltd. (JP) | 1997-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363115-A2 | CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE | CYP4F11, CYP11B1, CYP11B2 | GAA 3732/4885TDP1 1554/4885KMT2A 4235/4885 |
| US-20210163426-A1 | CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE | CYP4F11, CYP11B1, CYP11B2 | GAA 3938/4885TDP1 1463/4885KMT2A 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.